Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights significant financial risks with an 80% revenue decline and increased R&D expenses, leading to a substantial net loss. Clinical trial failures and regulatory uncertainties amplify the negative outlook. The Q&A reveals management's evasiveness on trial specifics, further eroding confidence. Lack of shareholder return initiatives and competitive market pressures exacerbate concerns. Without positive catalysts or strategic plans, the stock is likely to experience a strong negative reaction.
Key Financial Performance
Cash and Cash Equivalents $52.9 million as of December 31, 2024.
Total Revenue (Q4 2024) $15 million, a decrease of $58.5 million (80%) compared to $73.5 million in Q4 2023, primarily due to a decrease in collaboration revenue from agreements with GSK and Pfizer.
Total Revenue (Full Year 2024) $48 million, a decrease of $55.8 million (54%) compared to $103.8 million in 2023, primarily due to a decrease in collaboration revenue from agreements with GSK and Pfizer.
R&D Expenses (Q4 2024) $28.8 million, an increase of $12.2 million (73%) compared to $16.6 million in Q4 2023, primarily due to increased clinical trial activity related to the Phase 3 PIVOT-PO trial for tebipenem HBr.
R&D Expenses (Full Year 2024) $97 million, an increase of $45.6 million (89%) compared to $51.4 million in 2023, primarily due to increased clinical trial activity related to the Phase 3 PIVOT-PO trial for tebipenem HBr.
G&A Expenses (Q4 2024) $7.1 million, an increase of $0.7 million (11%) compared to $6.4 million in Q4 2023, primarily due to increased consulting and professional fees.
G&A Expenses (Full Year 2024) $23.7 million, a decrease of $1.9 million (7%) compared to $25.6 million in 2023, primarily due to decreases in personnel-related costs.
Net Loss (Q4 2024) $20.7 million, compared to a net income of $51.2 million in Q4 2023.
Net Loss (Full Year 2024) $68.4 million, compared to a net income of $22.8 million in 2023.
Diluted Net Loss per Share (Q4 2024) $0.38, compared to net income per share of $0.96 in Q4 2023.
Diluted Net Loss per Share (Full Year 2024) $1.27, compared to net income per share of $0.43 in 2023.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Tebipenem HBr: In a Phase 3 trial, tebipenem HBr is being developed as the first broad-spectrum oral carbapenem for treating complicated urinary tract infections (cUTIs). An interim analysis is expected in Q2 2025.
SPR720: SPR720, a gyrase B inhibitor for nontuberculous mycobacterial pulmonary disease, did not meet its primary endpoint in a Phase IIa trial, with potential safety concerns noted.
Market Positioning for Tebipenem HBr: Tebipenem HBr aims to address the unmet need for oral treatment options in complicated UTIs, potentially reducing hospitalization length.
Financial Position: As of December 31, 2024, Spero had cash and cash equivalents of $52.9 million, expected to fund operations into Q2 2026.
R&D Expenses: R&D expenses increased to $28.8 million in Q4 2024, primarily due to the Phase 3 trial for tebipenem HBr.
Discontinuation of SPR206: Spero has decided to discontinue the development of SPR206, an IV-administered next-gen polymyxin antibiotic.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Clinical Trial Risks: The Phase IIa trial for SPR720 did not meet its primary endpoint, showing insufficient separation from placebo and potential dose-limiting safety signals, including reversible grade 3 hepatotoxicity in the high-dose cohort.
Regulatory Risks: The success of tebipenem HBr is contingent on the completion of the Phase 3 trial and subsequent regulatory approval, which carries inherent uncertainties.
Financial Risks: A significant decrease in total revenue from $73.5 million in Q4 2023 to $15 million in Q4 2024, primarily due to reduced collaboration revenue from agreements with GSK and Pfizer.
Operational Risks: Increased R&D expenses from $16.6 million in Q4 2023 to $28.8 million in Q4 2024, indicating higher costs associated with clinical trial activities, which may impact financial stability.
Market Risks: The potential for competitive pressures in the biopharmaceutical market, particularly for treatments addressing multidrug-resistant infections, could affect market share and pricing.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Tebipenem HBr Phase 3 Trial: Spero's top priority is the continued advancement of the tebipenem program, with a prespecified interim analysis expected to be completed in Q2 2025.
SPR720 Development: The development of SPR720 has been paused following an interim analysis that did not meet primary endpoints, with further assessment of the full data set planned.
Discontinuation of SPR206: Spero has decided to discontinue the development of SPR206, an IV-administered next-gen polymyxin antibiotic.
Collaboration with GSK: If tebipenem HBr is approved, Spero could qualify for about $400 million in contingent milestones from GSK.
Cash Position: As of December 31, 2024, Spero had cash and cash equivalents of $52.9 million, expected to fund operations into Q2 2026.
Revenue Expectations: Total revenue for Q4 2024 was $15 million, down from $73.5 million in Q4 2023, with total revenue for 2024 at $48 million compared to $103.8 million in 2023.
R&D Expenses: R&D expenses for Q4 2024 were $28.8 million, up from $16.6 million in Q4 2023, primarily due to increased clinical trial activity.
Net Loss: Spero reported a net loss of $20.7 million for Q4 2024 and $68.4 million for the full year.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Spero Therapeutics has not announced any share buyback program or dividend program during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Does the trial get unblinded if the interim is successful?
A:If the interim is successful, yes, the interim process is going to be managed by an independent data monitoring committee. And if their recommendation is that we stop the trial or stop enrollment, the management team will be unblinded at that time.
Q:Is there any reason to keep running the trial longer in order to narrow some of the error bars for some of the subgroup analyses, like specifically in the ESBL positive population?
A:We can't speculate on that at the moment, given we're blinded and just preparing for the interim analysis. So we'll hopefully be able to respond to that once we've gotten the recommendation from the IDMC.
Q:What's the alpha spend on the interim?
A:We'll be spending a small amount of alpha for the prespecified IA. But since this is a prespecified interim, we've accounted for that alpha spend in determining the overall sample size for the study.
Q:Any comments you can make on the bar for success for the interim and when in the trial, it's actually conducted?
A:So basically, I mean, there are three scenarios that are likely, right? So either the trial meets the primary endpoint with this prespecified interim, which is the 10% non-inferiority margin, and we stop the trial or it fail or we stop the trial for futility or lastly, we continue enrolling.
Q:What are the potential paths forward for 720? And when can we expect an update?
A:The first step is to complete the data analysis of the full 25 patients dosed in the trial. Once we have the full picture on the data, we'll be in a better position to decide on the best path forward for the program, which may include a reformulation strategy.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer to the question regarding whether there is a reason to keep running the trial longer for subgroup analyses, indicating they cannot speculate due to the trial being blinded.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Chief Officer
Director Investor
Financial Officer
HBr Phase
IIa proof
IV imipenem
Interim Chief
Investor Relations
Keutzer Chief
MDR
NTM disease
Officer Chief
Officer Keutzer
Phase IIa
Rajavelu Interim
Senior Director
analysis patient
carbapenems
decision development
dose
hospitalization
imipenem cilastatin
infection UTIs
kidney
milligram hour
partner GSK
patient trial
placebo
product
reminder
risk uncertainty
statement risk
step program
treatment option
trial step
SPRO Transcript
Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript
Neutral8-12
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call reveals significant financial challenges, with a drastic revenue decline and increased losses. The clinical trial for SPR720 failed to meet its primary endpoint, posing risks. The lack of a shareholder return plan and increased R&D expenses further dampen sentiment. The Q&A section highlights management's uncertainty and lack of clear guidance, exacerbating concerns. Overall, the combination of financial struggles, clinical setbacks, and unclear strategic direction suggests a strong negative sentiment, likely leading to a significant stock price decline.
Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call highlights significant financial risks with an 80% revenue decline and increased R&D expenses, leading to a substantial net loss. Clinical trial failures and regulatory uncertainties amplify the negative outlook. The Q&A reveals management's evasiveness on trial specifics, further eroding confidence. Lack of shareholder return initiatives and competitive market pressures exacerbate concerns. Without positive catalysts or strategic plans, the stock is likely to experience a strong negative reaction.
Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript
Neutral8-9
SPRO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
